This study is for subjects who have been diagnosed with acute leukemia or myelodysplastic syndrome (MDS) and are a candidate for allogeneic hematopoietic stem cell transplant (HSCT). The study is being done to learn if adding defibrotide to the standard medicines for prevention of acute Graft-versus-Host Disease (aGvHD), which is called immunoprophylaxis, will help to prevent aGvHD better than using the usual immunoprophylaxis medicines alone. The investigational drug in this study is called Defibrotide. The duration of participation for each patient is approximately 6 months.
This study is for patients that have been diagnosed with follicular lymphoma. The investigational drugs used in this study are TGR-120 and Lenalidomide.The purpose of this study is to compare any good and bad effects of using the different drugs in combination with an antibody (Obinutuzumab). Participants can expect to be in this study for up to 5 years. There are 3 study groups. Groups 1 and 2 will get treatment on the study for 48 weeks (about 11 months). Group 3 will get treatment on the study for 42 weeks (about 9
The purpose of this study is to learn more about older adults (age 65 and older) with cancer and their overall health by completing a survey called a "geriatric assessment" (GA). A GA is designed to gather information about a patient's nutritional status, mental health, spiritual health, social support, and memory. In addition, it informs health care providers about how well you carry out your daily activities and collects information on the other health problems you may have.
This study is for patients that have been diagnosed with High Risk B-Lymphoblastic Leukemia (HR B-ALL). The investigational drug in this study is Ruxolitinib. The purpose of this study is to find out if the study drug, ruxolitinib, in combination with standard HR B-ALL treatment is safe and effective in children, adolescents, and young adults with HR B-ALL. Participants can expect to be in this study for the treatment period of approximately 26 months (females) or 38 months (males) plus the post-treatment follow-up. Subjects are considered on study during the post-treatment follow-up period until the subject is deceased, lost to follow-up, or until the study is completed. Subjects in this study will be followed until all enrolled subjects have been followed for 3 years from Day 1 or are deceased or lost to follow-up.
This study is for patients who have been diagnosed with acute myeloid leukemia (AML) with a genetic mutation called FLT3/ITD. The investigational drug in this study is called gilteritinib (ASP2215). The main purpose of this study is to learn if it is safe and effective to treat patients who have FLT3/ITD AML with a study drug called gilteritinib (ASP2215) after transplant. The sponsor wants to know if this drug works better than a placebo to stop the AML from coming back. Participants can expect to be in this study for up to 7 years after they start the study drug.
This study is for patients that have suffered a femur fracture due to metastatic cancer. The standard of care for this type of fracture is to stabilize the bone with an intramedullary nail. When preparing the femur for the nail, pressure can cause fat to enter the bloodstream and travel to the heart, causing heart and lung complications. The procedure being investigated in this study is called reduced pressure reaming. In this procedure the surgeon will use a device with suction when preparing the bone for the nail in order to decrease pressure and decrease the amount of fat that enters the bloodstream. Patients will be randomly assigned to either the standard preparation (standard reaming), or the reduced pressure preparation (reduced pressure reaming). After surgery, both treatment groups will followed according to standard practices at 2 weeks, 6 weeks, 3 months, and 6 months.
The primary objective of this study is to develop a blood-based gene expression signature, known as the ONC-LN-04 Lung Test, to be used in the detection of lung cancer in patients who underwent radiologic screening for lung cancer and had lung nodules detected. We intend to enroll volunteers who are being evaluated by a Ralph H. Johnson VAMC pulmonologist as part of their standard medical care. Participants will be current or former smokers, who have either (a) radiologic evidence of lung nodules, or (b) a confirmed diagnosis of non-small cell lung cancer (NSCLC) and has not undergone surgical excision, chemotherapy or radiation therapy for this malignancy. A single blood sample will be obtained from willing participants, then stored and analyzed for measurement of gene expression and development of the ONC-LN-04 test. Active participation in this study will be over once a blood sample is obtained; however, we may need access to participants' medical records post-enrollment and sample collection in order to monitor medical outcomes. Review of participants' medical records will occur until up to approximately 2,500 subjects have been enrolled and have provided clinical information and a blood sample.
This is a multi-center, non-randomized, single-arm, prospective trial to evaluate a staged sampling methodology designed to maximize the diagnostic yield of lung biopsy in a single procedure setting. Diagnostic yield will follow biopsy of peripheral pulmonary nodules as identified on chest CT utilizing (1) EMN bronchoscopy, and/or (2) EMN-TTNA.
This is a study that will test how an experimental drug (enfortumab vedotin) combined with a kind of anticancer drug called an immune checkpoint inhibitor (CPI) affects patients with cancer of the urinary system (urothelial cancer). This type of cancer includes cancer of the bladder, renal pelvis, ureter or urethra that has spread to nearby tissues or to other areas of the body.